TriSalus Reports 11% Revenue Growth in Q3
The Westminster-based medical device maker posted third-quarter 2026 revenue of $12.9 million and updated its full-year guidance.
Updated on Nov. 10, 2026 in Healthcare
TriSalus Life Sciences reported third-quarter 2026 revenue of nearly $12.9 million, up 11.3% from $11.57 million a year earlier, driven primarily by sales of its TriNav Infusion System. The company also updated its full-year 2026 revenue guidance to $46 million to $48 million.
Why it matters
The results show a narrowing of the company's losses, with the GAAP net loss from operations falling to $8.1 million from $10.8 million a year earlier. For Westminster, the figures reflect the financial trajectory of a local healthcare company as it works toward its stated goal of positioning itself for 2027.
Third-quarter 2026 revenue rose 11.3% to about $12.9 million, and the GAAP net loss from operations narrowed to $8.1 million from $10.8 million. The company had $41.1 million in cash or equivalents as of Sept. 30, and the source does not address how long that balance will fund operations.
The players
TriSalus Life Sciences
A Westminster-based medical device company traded on Nasdaq under the ticker TLSI that develops the TriNav Infusion System.
The details
TriSalus Life Sciences, which trades on Nasdaq under the ticker TLSI, attributed its revenue growth primarily to sales of the TriNav Infusion System, an advanced microcatheter. The company raised $46 million in the first quarter through an equity offering, and its net loss attributable to common stockholders for 2026 totaled $8.9 million, compared with $41.3 million in the prior-year third quarter.
Timeline
First quarter 2026: TriSalus raised $46 million through an equity offering.
Third quarter 2026 (quarter ended Sept. 30, 2026): The company reported revenue of $12.9 million, up 11.3%.
Sept. 30, 2026: TriSalus reported $41.1 million in cash and equivalents.
2027: The company says it believes it is well positioned for growth.
Market Landscape
The 11.3% revenue gain is driven by sales of the TriNav Infusion System, the product the company cites as its main growth engine. Against that backdrop, the company's updated 2026 guidance of $46 million to $48 million implies only modest expansion of roughly 2% to 6% over 2025, suggesting the product's growth is not yet translating into a sharp acceleration of the company's overall revenue.
Investors tracking TLSI can compare the updated $46 million to $48 million revenue guidance against the company's $41.1 million cash position as of Sept. 30. The narrowing of the net loss from operations to $8.1 million offers one concrete measure of progress for shareholders weighing the stock's near-term outlook.
The takeaway
The quarter shows steady top-line growth and a smaller operating loss, but the company's 2026 guidance points to modest expansion rather than rapid acceleration. Readers following TriSalus should watch whether the TriNav system's sales growth carries into the company's stated 2027 outlook.
Further reading
For more on the industry behind this report, explore Healthcare coverage on Wisevoter.
